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Abstract
Background: Over the last few decades, research regarding the age of onset of schizophrenia and its relationship
with other clinical variables has been incorporated into clinical practices. However, reports of potential differences
in demographic and clinical characteristics between early- and adult-onset schizophrenia spectrum disorders have
been controversial. Thus, this study aims to assess differences in demographic and clinical characteristics correlated
with age of illness onset in schizophrenia spectrum disorders.
Methods: Data were collected from 104 patients with schizophrenia and schizoaffective disorder. Diagnosis was
made via structured clinical interviews. Assessments of psychiatric symptoms and social and global functioning
were completed. The effect of age of onset on demographic and clinical variables was examined using correlation
analyses and binary logistic regression models. We chose 17 years of age as the cut-off for early-onset
schizophrenia spectrum disorders based on a recent clinical consensus. We further investigated differences in the
severity of psychopathology and other clinical variables between the early- and adult-onset groups.
Results: The binary logistic regression analysis showed that age of onset was significantly related to the cognitive
component of the Positive and Negative Syndrome Scale (PANSS) (odds ratio, OR = 0.58; 95% confidence interval,
CI = 0.872-0.985; p < 0.001) and Barratt Impulsiveness Scale (BIS) score (OR = 0.94; 95% CI = 0.447-0.744; p = 0.015).
Patients with early onset of schizophrenia spectrum disorders had significantly greater levels of cognitive
impairment and higher impulsivity. There were significant differences between several demographic and clinical
variables, including the negative symptom component of the PANSS (p < 0.001), cognitive component of the
PANSS (p < 0.001), BIS score (p = 0.05), and psychological domain of quality of life (QOL) (p = 0.05), between
patients with early- and adult-onset schizophrenia spectrum disorders, having controlled for the effect of the
current age and duration of illness.
Conclusions: Our findings support the hypothesis of an influence of age of onset on illness course in patients
with schizophrenia spectrum disorders. This finding may in fact be part of a separate domain worthy of
investigation for the development of interventions for early symptoms of schizophrenia.
Background
Schizophrenia is a complex, chronic, and disabling ill-
ness that presents with heterogeneity in its clinical
appearance, in patterns of psychopharmacological
response and in long-term outcomes [1,2]. While the
last few decades of research have given rise to a tremen-
dous wave of interest regarding the natural illness
course of schizophrenia, the overarching goal of this
research of influencing the prognosis and outcome for
schizophrenia patients remains pertinent today. The
validity of possible predictors of treatment response and
long-term outcome in schizophrenia patients has been a
topic of much study in recent years. However, the litera-
ture still lacks a clear-cut picture regarding which fac-
tors are valuably prognostic in the clinical management
of schizophrenia spectrum disorders.
Numerous empirical studies concentrate on the predic-
tive values of the variables detectable at the first episode of
schizophrenic illness for the long-term patient outcome.
Some practical factors, including sex and age at onset,
have been reported as being among the most important
determinants of the outcome of schizophrenia [3].
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general may have a later age of onset and an overall
lower severity of illness, suggesting a protective effect
of estrogens [4]. Several negative predictors of out-
come in schizophrenic patients have been identified,
including male sex [5], early and non-acute onset of
syndromes [6], the prevalence of negative symptoms
[7,8], the presence of affective symptoms [9], poor
pre-morbid functioning [10], and a delay in starting
pharmacological treatment [11]. All of these predictors
have been associated either with poorer long-term
global functioning or with higher rates of relapse or
hospitalisation. In particular, patients with schizophre-
nia with earlier ages of onset are more likely to be
males and to have poor pre-morbid adjustment, lower
educational achievement, more evidence of structural
brain abnormalities, more prominent negative symp-
toms, more cognitive impairment, and a worse overall
outcome [12] as well as a higher likelihood of having
relatives with schizophrenia [13,14].
The onset of schizophrenia prior to age 13 is exceed-
ingly rare [15], but an estimated 39% of males and 23%
of females with schizophrenia develop the illness by
the age of 19 [16]. Patients with early-onset schizo-
phrenia (EOS; onset by age 18) [17], including child-
hood-onset schizophrenia (COS; onset by age 13) [16]
and adolescent-onset schizophrenia (AOS; onset after
age 13 and before age 18) show a number of the same
neurobiological abnormalities observed in adult-onset
schizophrenia, suggesting the involvement of a com-
mon neurobiological substrate [17,18]. However, com-
pared to patients with adult-onset schizophrenia, an
early onset of schizophrenia appears to be associated
with higher rates of pre-morbid abnormalities [17,19],
worse cognitive performance [20] and worse functional
outcomes [21]. Taken together, these studies indicate
that EOS may result in a more severe form of the
disorder.
While age of onset and sex have been documented to
be fundamental for understanding schizophrenia and
bipolar disorder separately [3,22], there is also substan-
tial clinical and neuropsychiatric overlap between these
two disorders. We have embodied this overlap in schi-
zoaffective disorder, a diagnostic category with features
of both schizophrenia and affective disorders but with
poor construct validity [23]. The current diagnostic sys-
tem has been further called into question by recent stu-
dies indicating shared genetic determinants of bipolar
disorder and schizophrenia [24]. In spite of these over-
laps, there has been little research examining the char-
acteristics and symptoms of psychosis within both
schizophrenia and bipolar disorder, which could yield
evidence of commonalities as well as differences among
patients with psychosis [25].
In this study, we estimated the relationship of age of
onset to other clinical characteristics in well-classified
patients diagnosed with schizophrenia spectrum disor-
ders. We also compared psychopathology and other
clinical variables between schizophrenia and schizoaffec-
tive patients with early and adult onset. With regard to
the age of onset and classification of types of schizo-
phrenia or schizoaffective disorder, previous studies
have adopted cut-off points. For instance, a review of
adolescent research used the age of 17 to distinguish
child- and adolescent-onset from adult-onset schizo-
phrenia [26]. Because 17 years of age is the cut-off
found in most studies and clinical settings [26], we
selected 17 years as the cut-off for early-onset
schizophrenia.
Methods
Participants
A total of 113 inpatients with a Diagnostic and Statisti-
cal Manual of Mental Disorders, Fourth Edition (DSM-
IV) [12] diagnosis of schizophrenia (N = 59) or schizoaf-
f e c t i v ed i s o r d e r( N=5 4 )r e c r u i t e df r o ma m o n ga l l
patients hospitalised at one psychiatric service during
the continuous one-year period of time selected for the
study, were individually participated in the study. All
patients who had experienced an illness duration of over
one year were eligible for recruitment from the chronic
inpatient unit of a general hospital, where they had to
have been hospitalised for treatment of an acute psycho-
tic exacerbation for at least 60 days before recruitment.
Prior to commencing the study, ethical approval was
obtained from the Institutional Review Board of Tri-ser-
vice General Hospital, National Defense Medical Center
in Taiwan. Following a comprehensive explanation of
the study, subjects were asked to give their written
informed consent. Of the 113 inpatients initially invited
to participate in the study, 9 refused to participate,
yielding a final sample of 104 subjects (92% of the initial
sample). Subjects were between the ages of 19 and
60 years. Of the final sample, 52 patients were diagnosed
with schizophrenia and 52 with schizoaffective disorder.
Subsequent to the initial evaluation, participants also
underwent a comprehensive screening and assessment.
The clinical procedure used for this purpose involved
the administration of a structured clinical interview, a
detailed medical history review and physical examina-
tions. Patients who had evidence of organic brain
pathology including cerebral tumour, epilepsy, systemic
disease, history of cranial trauma, brain surgery, or his-
tory of substance abuse or dependence in the past or
present were excluded from this study. To obtain this
information, the interviewer systemically inquired about
the chronology of psychotic symptoms and the level of
impairment they produced. Prior to entering the study,
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Page 2 of 11only 1% (n = 1) of the patients were taking typical or
first-generation antipsychotics (Haloperidol), and 99%
(n = 103) were taking atypical antipsychotics, including
Risperidone (17%; n = 17); Quetiapine (21%; n = 22);
Amisulpride (7%; n = 9); Aripiprazole (13%; n = 13);
Ziprasidone (1%; n = 1); Zotepine (4%; n = 4); Olanza-
pine (5%; n = 5); and Clozapine (32%; n = 32). Finally,
18 patients (n = 18) had been prescribed antipsychotic
depot medications (Haloperidol decanoate n = 15; and
Risperidone Consta n = 3). The antipsychotic prescrip-
tions for 85 subjects had been unchanged for at least
three months prior to their recruitment, and only 19
subjects had undergone small changes in their prescrip-
tions during the six months prior to recruitment. These
19 subjects were evaluated as clinically stable by the
responsible psychiatrist.
Baseline demographic data consisted of gender, age,
educational level, and body mass index (BMI). A semi-
structured interview to determine the age of illness
onset, the duration of illness, and recurrence of previous
hospitalizations was obtained from the one responsible
psychiatrist. Note that data were also extracted from all
available information, including hospital records and
information from family members. The age of illness
onset was defined as the age when the patient met
DSM-IV criteria [12] for the first time. The duration
of the illness was defined as the time since the first
psychotic episode.
Measures
The following assessmentsw e r ea d m i n i s t e r e da tt h e
same time with reference to the respondent’s behaviour
and experience over the previous 12 months.
The Self-Appraisal of Illness Questionnaire (SAIQ)
was used to assess attitudes toward schizophrenia
among patients receiving psychiatric treatment. The
SAIQ is an assessment tool developed for use in the
clinical setting that was derived closely from the concept
of the Patient’s Experience of Hospitalization (PEH)
questionnaire [27]. This scale is a self-report instrument
composed of 17 items. Participants were asked to rate
the extent to which they agreed with each statement by
using a four-point Likert scale ranging from 0 (i.e., “do
not agree at all”) to 3 (i.e., “agree completely”). The
internal consistency of the scale was 0.867 and the test-
retest reliability was 0.82. It was concluded that the
Need for Treatment and Presence/Outcome of Illness
subscales could be used as brief screening instruments
for clients with schizophrenia who may be at risk for
treatment non-compliance due to a lack of insight into
their illness [27]. Lower SAIQ subscale scores indicate
less awareness of one’s psychiatric illness.
The patients’ global psychopathology was evaluated with
the Positive and Negative Syndrome Scale (PANSS) [28].
The PANSS was developed in an attempt to provide a
more comprehensive assessment of the symptoms of
schizophrenia. It is widely used in clinical and research
settings and is regarded as a reliable means of symptom
assessment. In the present study, four analytically-derived
PANSS components were used: positive component,
negative component, cognitive component and total
score [28].
Action without planning or reflection is central to
most definitions of impulsivity. Prior research has
demonstrated that impulsivity is a considerably complex
behavioural construct [29]. To quantify impulsivity, the
Barratt Impulsiveness Scale (BIS) was used as a self-
report assessment [30]. This scale relies mainly on
subjects’ recall of behaviours or attitudes. It contains
30items measuring three aspects of impulsivity. Atten-
tional/cognitive impulsivity is a lack of cognitive persis-
tence with an inability to tolerate cognitive complexity;
motor impulsivity is a tendency to act impulsively; and
non-planning impulsivity refers to a lack of sense of the
future [30].
The Beck Depression Inventory (BDI) is a 21-item self-
report scale [31]. Each item consists of four alternative
statements that reflect gradations in the intensity of
a particular depressive symptom (rated in severity from
0 to 3). The results are scored by summing the responses
to each of the items to obtain a total depression score
(range = 0-63). The psychometric properties of the inven-
tory have been reviewed by Beck and Steer [31].
The Anxiety Checklist (ACL) was designed to assess
the severity of anxiety symptoms in depressed patients
[32]. This scale consists of 21 items that represent
somatic, affective, and cognitive symptoms. The ACL
has been shown to exhibit good internal consistency
(alpha = 0.92) and test-retest reliability, r(58) = 0.75,
over one week [32].
The Beck Hopelessness Scale (BHS) is a 20-item true-
false self-report instrument that assesses the degree of
pessimism exhibited by an individual [33]. Each of the
20 items is scored as either 0 or 1. The total score is the
sum of the individual item scores (range = 0-20). In a
sample of 294 hospitalised patients who had attempted
suicide, the Kuder-Richarson reliability (KR21) coeffi-
cient for the Beck Hopelessness Scale was 0.93, and all
of the item-total correlations, ranging from 0.39 to 0.76,
were significant [33].
To assess patients’ present suicidal risk, the Scale for
Suicide Ideation (SSI), which includes 19 items that
evaluate the severity of current suicidal ideations and
wishes, was used [34]. It is based on clinical systemic
observations and interviews with suicidal subjects. Each
item is composed of three choices that range from 0
(least severe) to 2 (most severe). The total score is
obtained by summing the item ratings yielding total
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quency and duration of suicidal thoughts as well as
patients’ attitudes towards them [34].
In this study, the comprehensive strategy for evaluat-
ing the patients’ quality of life (QOL) involved two
main domains: clinician-rated (objective) and self-rated
(subjective) assessments. The objective evaluation of
clinical course and social functioning of the patient was
based on the Global Assessment of Functioning (GAF),
which is a measure of overall psychological disturbance
as rated by the clinician [12]. In addition, the Taiwanese
version of the WHOQOL-BREF was used as the subjec-
tive aspect-specific scale in this study. Like the standard
WHOQOL-BREF questionnaire, it defines four domains
related to QOL (physical health, psychological health,
social relationships, and environment) and measures the
facets of QOL and general health [35,36]. It contains 28
items, including 26 standard items from the WHO-
QOL-BREF and two culturally relevant items [35,36].
The 26 standard items are comprised of one item from
each of the 24 facets of the WHOQOL-100 and two
items from the overall QOL and general health facet. In
a study by Yao et al. [36], exploratory and confirmatory
factor analyses of the Taiwanese version of the WHO-
QOL-BREF revealed a four-factor model (physical
health, psychological health, social relationships and
environment). Internal consistency (Cronbach’sa l p h a )
coefficients ranged from 0.7 to 0.77 for the four
domains. Test-retest reliability coefficients with intervals
of two to four weeks ranged from 0.41 to 0.79 at the
item/facet level and 0.51-0.64 for inter-domain correla-
tions (all p < 0.01). In the present study, the four
domain scores (physical health, psychological health,
social relationships and environment) were calculated
by the standard scoring algorithms of the Taiwanese
version of the WHOQOL-BREF. Scores ranged from 4
to 20. Additionally, the two items measuring overall
quality of life (Facet G1: In general, how would you
evaluate your quality of life?) and general health (Facet
G4: In general, are you satisfied with your health?) were
averaged to represent overall health-related QOL
[35,36].
Statistical analysis
All statistical tests were carried out using the Statistical
Package for the Social Science (SPSS), version 15.0 for
Windows.
Data analysis was conducted in three phases. Initially,
comparisons of demographic and clinical variables
between the schizophrenia and schizoaffective groups
were conducted using independent samples t-tests and
Mann-Whitney U-tests for continuous and categorical
variables, respectively. Additionally, given the theoretical
positions taken for the study as briefly reviewed above,
two analytical approaches were applied in our study.
Spearman’s correlation coefficient was used to assess
relationships between the age of illness onset and insight
into illness, psychopathology, symptom rating scales,
and QOL variables. For exploratory analysis of associa-
tions with clinical variables, the age of illness onset fac-
tor was dichotomised. We chose 17 years of age as the
cut-off for early-onset schizophrenia based on a recent
international consensus [26]. Subjects who were aged 17
or younger were considered early-onset, and subjects
older than 17 years were considered adult-onset cases
[26]. To identify predictive variables, binary logistic
regression models were created using the forward step-
wise method to identify clinical variables that were good
predictors of age of illness onset. To assess the effects of
age of onset separately from influences of current age
and duration of illness, binary regression analysis was
repeated after removing any significant independent pre-
dictors for which associations were simply due to the
effects of current age and duration of illness. All vari-
ables that were significant (p < 0.01) or showed a trend
toward significance (p < 0.05) in univariate analyses
were included in the regression analyses (details of the
included variables are presented in the results section).
As our study was exploratory, we considered trends as
well as significant findings. In this study, we decided to
apply a stepwise regression because we needed to bal-
ance sensitivity and utility. We also identified enough
predictors to be sufficiently sensitive to explain the
patients’ ages of illness onset, but few enough to avoid
interaction effects that could result in utility problems
[37]. The Wald test was used to examine the effects of
the explanatory variables. Finally, the present study
compared psychopathology and other clinical character-
istics between early- and adult-onset illness. The com-
parison was made by splitting the patients into two
groups based on age of onset, then using univariate
two-way analysis of covariance (ANCOVA) to identify
differences between early- and adult-onset patients in
the remaining demographic and clinical variables. To
control for the effects of current age and duration of ill-
ness, these factors were regarded as covariates in the
ANCOVAs.
Results
Participants’ characteristics and clinical evaluations
The average age of patients at the time of assessment
was 39.24 years (standard deviation [SD] = 10.29), ran-
ging from 19 to 60 years, and the mean duration of
receiving education was 12.88 years (SD = 2.75), ranging
from 9 to 18 years. Fifty-two (50%) of the patients were
male and fifty-two (50%) were female. Marital statuses
of the patients were as follows: 10 (10%) married,
78 (75%) unmarried, and 16 (15%) divorced or widowed.
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range (less than 25), 29% (n = 30) were overweight, and
15% (n = 16) were obese (greater than 30). The mean
age of illness onset was 24.14 years (SD = 7.58 years;
range: 15-51 years); the mean illness duration was
15.1 years (SD = 8.56 years; range: 4-37); and patients
had an average of 7.24 previous hospitalisations
(SD = 4.28 years; range: 2-25).
A breakdown of demographic and clinical characteris-
tics by diagnosis is presented in Table 1. The two
groups were similar in terms of sex, current age, age of
illness onset, illness duration, previous hospitalisations,
and some clinical rating scales (all p-values > 0.05).
Patients with a diagnosis of schizophrenia had signifi-
cantly higher QOLs according to the total score and
four domain scores, whereas patients with a diagnosis of
schizoaffective disorder had higher SAIQ, PANSS, BDI,
and BIS scores (all p-values < 0.05).
Correlation and regression analyses of age at illness
onset
To evaluate the relationship between age of illness onset
and these clinical characteristics, a series of correlational
analyses (Spearman’sr h o )w a sc o n d u c t e d .T h ea g eo f
onset for all subjects was found to be significantly corre-
lated with insight into outcome/presence of illness
(Spearman’s rho = -0.21, p < 0.05), PANSS components,
except for the positive component, and total scores
(Spearman’s rho = -0.199 to -0.257, p < 0.01), BIS total
and subscale scores (Spearman’s rho = -0.266 to -0.354,
p < 0.01), and QOL total and domain scores, with the
exception of the environmental domain (Spearman’s rho
= 0.248 to 0.336, p < 0.01), but it was not correlated
with sex, education, previous hospitalisations, BDI, ACL,
BHS, SSI or GAF. Because a large number of correlation
factors were examined in this analysis, the threshold for
significance was set at p < 0.05.
Table 1 Means (and SD) of demographic and clinical characteristics for the schizophrenia (n = 52) and schizoaffective
(n = 52) groups
Schizophrenic disorder Mean (SD) Schizoaffective disorder Mean (SD) t Significance
Age 40.23 (10.06) 38.25 (10.51) 0.982 0.329
Education 12.88 (2.66) 12.88 (2.86) 0.000 1
BMI 24.95 (5.23) 25.27 (4.03) -0.354 0.724
Age of illness onset 25.56 (7.94) 22.73 (6.98) 1.927 0.06
Illness duration 14.67 (8.85) 15.52 (8.33) -0.502 0.617
Previous hospitalization 6.51 (3.80) 7.96 (4.64) -1.734 0.086
SAIQ need for treatment 10.13 (2.90) 11.31 (3.25) -1.941 0.055
SAIQ presence/outcome of illness 8.29 (3.27) 9.88 (3.78) -2.303 0.023*
PANSS positive 15.13 (3.44) 15.48 (3.44) -0.513 0.609
PANSS negative 19.25 (5.32) 19.11 (4.50) 0.139 0.889
PANSS cognitive 19.35 (5.16) 21.79 (4.25) -2.633 0.01*
PANSS total score 73.71 (16.33) 80.38 (12.51) -2.339 0.021*
BIS motor 14.67 (5.38) 16.63 (5.97) -1.76 0.081
BIS attention 9.21 (4.52) 11.25 (4.68) -2.26 0.026*
BIS non-planning 15.25 (5.53) 16.90 (4.81) -1.628 0.107
BIS total score 39.13 (13.28) 44.79 (12.75) -2.215 0.029*
BDI 12.25 (10.14) 16.87 (12.78) -2.056 0.042*
ACL 14.52 (13.7) 17.79 (15.47) -1.115 0.252
BHS 6.42 (4.23) 6.52 (4.32) -0.115 0.909
SSI 3.56 (5.33) 4.71 (7.16) -0.932 0.353
QOL G1F 3.29 (0.8) 2.88 (0.81) 2.56 0.012*
QOL G4F 3.29 (0.91) 2.58 (1.07) 3.64 <0.001**
QOL physical 23.10 (4.53) 21 (3.71) 2.58 0.011*
QOL psychological 19.0 (4.14) 16.27 (4.12) 3.37 0.001**
QOL social 12.98 (4.35) 10.88 (3.01) 2.86 0.005**
QOL environmental 26.60 (6.33) 25.79 (4.58) 0.745 0.458
QOL total score 81.67 (13.99) 73.94 (11.75) 3.05 0.003**
GAF 52.01 (13.0) 50.67 (10.0) 0.592 0.555
*p < 0.05; **p < 0.01
Abbreviations: SAIQ = Self-Appraisal of Illness Questionnaire; PANSS = Positive and Negative Syndrome Scale; BIS = Barrett Impulsiveness Scale; BDI = Beck
Depression Inventory; ACL = Anxiety Checklist; BHS = Beck Hopelessness Scale; SSI = Scale for Suicide Ideation; QOL = Quality of Life; GAF = Global Assessment
of Functioning.
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binary regression (Table 2), we examined the relation-
ship of candidate predictors to age of onset in models
including sex, education, total number of previous hos-
pitalisations, two SAIQ scores that assessed global
insight into illness, and scores on the PANSS, BIS, BDI,
ACL, BHS, SSI, QOL, and GAF as independent variables
and the current age and duration of illness as a priori
confounding independent variables. The analysis
resulted in two models predictive of age of onset. The
first model (-2 log likelihood = 88.27, c
2 = 10.63, p <
0.001) contained only one predictor: cognitive impair-
ment (odds ratio, OR = 0.732; 95% confidence interval,
CI = 0.62-0.864). The second model (-2 log likelihood =
83.32,c
2 = 15.58, p = 0.015) contained two predictors:
impulsivity traits (OR = 0.94; 95% CI = 0.447-0.744) and
cognitive impairment (OR = 0.58; 95% CI = 0.872-
0.985). We found that both cognitive impairment and
impulsivity traits, as rated with the PANSS and BIS,
respectively, were inversely related to age of onset in
this sample of stabilised, schizophrenia spectrum
disorders.
Mean test scores for age of onset groups (ANCOVAs)
Mean test scores for early- and adult-onset patients are
presented in Table 3. After adjusting for current age
and illness duration, early- and adult-onset patients had
significantly different clinical characteristics. No differ-
ences were found in education, previous hospitalisations,
PANSS positive component, SAIQ, several symptom rat-
ings, and QOL, with the exception of the psychological
domain, between early- and adult-onset patients. As pre-
sented in Table 3, early-onset patients had significantly
higher scores on the negative and cognitive domains
and total score on the PANSS as well as the BIS atten-
tional and non-planning subscales and total score. How-
ever, the mean score in the psychological domain of
QOL in early-onset patients was lower than that in the
group of adult-onset patients (all p-values < 0.05).
Discussion
Among the numerous clinical characteristics used to
clarify the schizophrenia spectrum disorders, the age of
illness onset is widely accepted as having particularly
powerful clinical and prognostic significance. The com-
plexity and variety of effects of the age of onset in schi-
zophrenia patients reported in the literature are due not
only to the difficulty in operationally defining the age of
illness onset but also to the broad distribution of ages of
onset from preadolescence to later adulthood. In this
cross-sectional study, there was evidence for statistically
significant relationships between age of onset and cogni-
tive impairments and impulsivity traits in this group of
schizophrenia spectrum disorders. Patients with early
onset had higher levels of cognitive impairments and
impulsivity traits than did patients with adult onset.
This is compatible with the generally accepted view of
early-onset cases as having unique clinical and prognos-
tic consequences. However, we do not have any evi-
dence for a causal relationship between age of onset and
cognitive impairments and impulsivity traits. No defini-
tive conclusion can be drawn until longitudinal prospec-
tive studies are carried out.
The mean age of onset for all schizophrenia patients
who participated in this study was slightly older than is
generally reported in populations of schizophrenia
patients [38], particularly when recorded as the year of
life when the subject first met DSM-IV [12] criteria. A
possible explanation is that a large proportion of our
patients (about 70%) presented with the paranoid type
of schizophrenia, which is characterised by a consider-
ably older age of onset (mean age of 28.5 years vs. 19.9
years in patients with non-paranoid schizophrenia). The
present results also show that schizophrenia patients
were not different from patients with schizoaffective dis-
order in terms of age of onset. There is a growing body
of research specifically regarding early-onset schizophre-
nia [16-18], but research regarding youths with schizoaf-
fective disorder is sparse [39]. In fact, most studies
include schizoaffective disorder as an exclusionary cri-
terion or combine both diagnoses into one group for
data analysis [39]. Further complicating matters is the
fact that these diagnoses are often contingent on a long-
itudinal illness course, yet diagnosis is generally made
using cross-sectional information. The DSM-IV diagnos-
tic criteria for schizoaffective disorder require that mood
episodes be present for a substantial portion of the
duration of the illness [12]. This diagnostic assignment
may change over time as the course and presentation of
psychotic symptoms become obvious [39,40]. For exam-
ple, in the clinical setting, a patient’sd i a g n o s i sc a n
change from schizophrenia at baseline to schizoaffective
disorder at discharge [40]. Further research will be
Table 2 Multivariate logistic regressions (stepwise) with
age of illness onset as the dependent variable
Predictors Beta SE Wald Significance OR 95% CI
Step 1
Cognitive -0.312 0.085 13.538 <0.001 0.73 0.62-0.864
Constant 8.488 2.023 17.606 <0.001 0.057
Step 2
Impulsivity -0.076 0.031 6.065 0.015 0.94 0.872-0.985
Cognitive -0.551 0.13 17.948 <0.001 0.58 0.447-0.744
Constant 6.824 2.235 9.325 0.002 0.021
Abbreviations: Cognitive = cognitive component of the Positive and Negative
Syndrome Scale; Impulsivity = total score of Barratt Impulsiveness Scale; OR =
Odds ratio; CI = Confidence Interval.
Kao and Liu BMC Psychiatry 2010, 10:63
http://www.biomedcentral.com/1471-244X/10/63
Page 6 of 11needed to help clinicians distinguish schizophrenia from
schizoaffective disorder in patients with early-onset schi-
zophrenia. Despite this, one of the most salient and
overarching findings of our study is that the patients
with schizophrenia and schizoaffective disorder are
more similar than different in terms of their demo-
graphic and symptom profiles. Our findings provide
additional support for shared etiological and pathophy-
siological features across schizophrenic disorder groups.
Such information will have important prognostic and
treatment implications.
Researchers have shown that age of onset may not
necessarily act as a unique determinant in the course of
schizophrenic disorder as evidence indicates that men
have an earlier age of illness onset than women [3-6]
and a more severe course of illness, particularly in the
short and medium terms [41]. A remarkable finding in
the present study was that we were not able to establish
differences between male and female patients in demo-
graphic variables, including age at onset and symptom
severity, or in total scale or subscale scores. This is in
contrast with previous studies that found symptomatic
differences between the sexes. In these previous studies,
negative symptoms were consistently found to be more
severe in men [42]. This discrepancy might be due not
only to differences in the rating scales applied but also
to sample differences. The lack of evidence for a sex dif-
ference is difficult to explain. Our patients’ mean age
(mean age = 40.57 years) was higher than those of other
studies [43], the female patients (mean age = 41 years)
were older than the males (mean age = 40 years), and
female patients (mean duration = 15.25 years) had a
longer illness duration than males (mean duration =
14.94 years); this might be related to a putative progres-
sive reduction in symptom differences. The results indi-
cate that the differences in clinical characteristics of
schizophrenic disorders between early- and adult-onset
patients may be more pronounced than those between
patients of different sexes, but an interaction effect
might be present between sex and age of onset.
Table 3 Means (and SD) test scores for early-onset and adult-onset schizophrenia spectrum disorders and the results
of an ANCOVA with current age and duration of illness as covariates
Early onset (n = 19) Adult onset (n = 85)
Mean SD Mean SD F(df = 103) Significance
Education level
a 12.0 2.00 13.38 2.86 0.052 0.821
BMI 26.28 6.29 24.85 4.20 2.373 0.127
Previous hospitalisations 7.37 3.93 7.21 4.38 0.004 0.95
SAIQ need treatment 10.63 3.34 10.74 3.09 0.069 0.793
SAIQ presence/outcome 9.47 3.52 9.00 3.64 0.308 0.58
PANSS positive 15.26 3.45 15.32 3.45 0.000 0.988
PANSS negative
a 22.84 4.35 18.36 4.66 13.134 <0.001**
PANSS cognitive
a 24.63 4.07 19.66 4.57 14.919 <0.001**
PANSS total score
a 86.37 13.63 74.96 14.38 6.236 0.014*
BIS motor
a 18.79 5.99 14.95 5.48 1.114 0.294
BIS attentional
a 13.11 4.83 9.59 4.44 3.974 0.049*
BIS non-planning
a 19.58 4.06 15.29 5.15 3.998 0.047*
BIS total score
a 51.47 12.32 39.84 12.57 3.938 0.05*
BDI 17.89 13.89 13.79 11.13 0.092 0.763
BAI 19.00 16.01 15.52 14.14 0.07 0.792
BHS 7.21 4.5 6.31 4.21 0.414 0.646
SSI 3.68 6.90 4.24 6.21 0.777 0.38
QOL G1F
a 2.68 1.00 3.18 0.76 1.035 0.312
QOL G4F
a 2.26 0.93 3.08 1.03 2.707 0.103
QOL physical 20.52 4.41 22.39 4.17 0.233 0.063
QOL psychological
a 15.05 4.93 18.21 4.0 3.936 0.05*
QOL social
a 10.32 3.61 12.29 3.85 0.403 0.527
QOL environmental 25.58 5.88 26.33 5.46 0.001 0.971
QOL total score
a 71.47 15.04 80.23 12.71 0.826. 0.366
GAF 47.63 8.72 52.18 11.99 1.895 0.172
*p < 0.05; **p < 0.01
a Indicates significant differences in paired t-test
Abbreviations: SAIQ = Self-Appraisal of Illness Questionnaire; PANSS = Positive and Negative Syndrome Scale; BIS = Barrett Impulsiveness Scale; BDI = Beck
Depression Inventory; ACL = Anxiety Checklist; BHS = Beck Hopelessness Scale; SSI = Scale for Suicide Ideation; QOL = Quality of Life; GAF = Global Assessment
of Functioning.
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apparent in our chronic schizophrenic patients, espe-
cially in early-onset cases. The findings of the current
study and the study of Hoff et al. (1992) indicate a more
generalised, diffuse cognitive deficit in chronic schizo-
phrenic disorders [44]. Our results also support the
assertion of the DSM-IV (1994) that schizophrenia
patients with younger ages of onset are more cognitively
impaired [12]. It seems that an earlier onset of schizo-
phrenia is associated with a more severe course irrespec-
tive of duration of illness [45]. Given its cross-sectional
nature in this study, however, no conclusion can be
drawn regarding causality and alterative explanations of
the findings cannot be ruled out. For instance, it is pos-
sible that patients with adult onset had better response
to antipsychotic medications, thereby reducing their
severity of symptoms. Specifically, we used the cognitive
component of the PANSS to assess cognitive function in
patients with schizophrenia. It has been documented
that higher scores on the PANSS cognitive component
are significantly correlated with poorer performance on
neuropsychological tests [46].
Action without planning or reflection is central to
most definitions of impulsivity. In the present study, we
used the BIS questionnaire, which tends to measure
impulsivity as a stable characteristic, as a self-reported
assessment of impulsivity [30]. There were significant
associations between early age of onset and severity of
impulsivity traits. Previous reports have suggested that
schizophrenic patients are likely to exhibit impairments
on a wide range of neuropsychological tasks, including
attention and executive functioning [47]. Heaton et al.
(2001) showed that the neuropsychological impairment
in patients with schizophrenia appeared to remain stable
regardless of baseline characteristics and changes in
clinical state [48]. Reduced P300 amplitude, a neurophy-
siological parameter associated with impulsivity and
behaviour disinhibition [49], and a P300 effect size (d)
that was smaller in amplitude and longer in latency
have been observed in schizophrenic patients compared
to normal controls, with the strongest effects obtained
from the auditory oddball task [50]. Therefore, it is
plausible that psychopathological and neurocognitive
impairments in schizophrenic patients are mediator vari-
ables responsible for the effect of impulsivity on the age
of onset in schizophrenia spectrum disorders. The
results reported in the present study support this rela-
tionship. Because impulsivity is present as a relatively
stable trait, it would appear that greater impulsivity is
already present at onset in early-onset schizophrenia.
However, no definitive conclusion can be drawn until
further prospective studies are performed.
Compared with the regression model, significant effects
of age at onset were found in the negative symptom
component, cognitive component, and the total score,
but not in the positive component of the PANSS in the
ANCOVAs. Patients with early illness onset scored
higher on negative symptoms, cognitive symptoms, and
general psychopathology than did patients with adult-
onset illness. To further evaluate the magnitude of the
predicted difference, an effect size test was conducted.
The standardised effect size difference for cognitive
impairment between groups was 0.387, reflecting a med-
ium-sized effect [51]. Moreover, the standard effect sizes
for negative symptoms and impulsivity traits were 0.427
and 0.511, respectively, also reflecting medium-sized
effects [51]. However, the standardised effect size differ-
ence for positive symptoms between groups was 0.121,
reflecting a smaller effect size [51]. These results agree
with those of some previous systemic studies [52]. Simi-
larly, some studies have reported that negative thought
disorder was less severe in patients with older ages of ill-
ness onset. However, there was no effect of age of onset
on the depressive symptoms in this study, a finding that
is consistent with other comprehensive studies [4,52].
Together, given the exploratory nature of these studies,
these data suggest that any phenomenon related to age of
onset in schizophrenia based on these preliminary find-
ings should be treated with caution.
In the present study, considering the results of t-tests
for differences between the early-onset and adult-onset
groups, it was expected that education would be related
to age of onset as patients should have completed less
schooling if their first episode occurred when they were
still attending school. A likely explanation is that our
patients with earlier ages of onset had poor educations
due to the cognitive dysfunction associated with poorer
outcomes in early-onset schizophrenia [12,53]. However,
this significant effect was appreciably reduced after con-
trolling for illness duration and current age. The find-
ings suggest that the difference in the educational levels
between the two groups may be strongly affected by ill-
ness duration and current age. It is difficult to estimate
the confounding influence of illness duration on our test
results due to the retrospective design.
It is uncertain, however, whether the effects of age of
onset found in the present study reflect qualitatively
specific schizophrenia or merely quantitative differences
in psychopathology and impulsivity between early- and
adult-onset illness in our patients. One recent study
reported that the relationship between an older age of
onset and less severe negative symptoms is also present
in chronically ill schizophrenic patients with an age of
onset of younger than 45 years [54]. Thus, future
research is needed in this area, particularly concerning
the potential consequences of age of onset, utilising dif-
ferent clinical measures (especially as the results indicate
that early onset is a risk factor) and a broader array of
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nic disorders.
In stabilised schizophrenic patients, assessment of sub-
jective QOL has good reliability and concurrent validity
[55,56]. Hence, measurement of subjective QOL may be
considered as a pertinent indictor of the state of health
of stabilised schizophrenic patients [56]. The present
study tested the relationship of age of onset with the
QOL of patients with schizophrenia spectrum disorders
by using t-tests. The results showed that patients with
an early onset of schizophrenia spectrum disorders were
likely to have worse QOLs than those with an adult ill-
ness onset. A partial explanation for this may lie in the
fact that an early onset of illness has been found to be a
predictor of unfavourable prognosis and is correlated
with higher global severity [57], higher rates of chroni-
city, and more probable impairments in cognitive per-
formance [58]. However, this significant effect was
largely reduced after controlling for illness duration.
The findings suggest that the difference in QOL levels
between the two groups may be strongly affected by ill-
ness duration. Besides, in patients with schizophrenia,
adaptation and significant improvement in subjective
QOL may be assumed to occur at a later stage of illness
[59]. This finding is compatible with the results of our
study, which showed that older patients are more satis-
fied with their lives than younger patients are. (Pearson’s
r = 0.218, p < 0.01).
There are some limitations of our research. First, only
inpatients in the chronic setting were recruited in the
present study. The results could not demonstrate
whether the effect of age of onset as measured in our
study indicates a trait or state characteristic. Addition-
ally, we could not generalise our findings to all schizo-
phrenia subjects. Thus, replication of the current
findings in stabilised outpatients will be necessary. Sec-
ond, because the present study required informed con-
sent and included psychopathological assessments, we
did not include subjects who were very uncooperative.
Thus, we lack demographic characteristics of non-volun-
teers. However, it should be noted that those unco-
operative subjects were demographically different from
the volunteers, and thus the influence of our results
m i g h tb el i m i t e d .T h i r d ,a sn oted above, the size of the
early-onset group was relatively small, which likely lim-
ited our ability to detect group differences due to low
statistical power, but this may reflect a greater preva-
lence of adult-onset schizophrenic disorder cases [16].
Fourth, it is important to emphasise that methodological
problems such as the retrospective design limit our
interpretation. All data on the illness course, however,
were based on information documented at the time of
inpatient treatment, including the age of onset of the
first psychotic episode and other demographic and
clinical characteristics, which can be biased by recall
effects. Thus, a prospective comparison of characteristics
at illness onset of patients with schizophrenia spectrum
disorders will be necessary for future research. Finally,
given the retrospective design of our study, the psycho-
pharmacological variables were not controlled a priori,
and thus it was not possible to determine the effects of
the medications on some aspects of cognition and the
clinical course of the disease.
Conclusions
In summary, the present study showed that the variance
of demographic and clinical characteristics in schizo-
phrenia spectrum disorders may be greater between
early- and adult-onset patients than between patients of
different sexes. The findings are roughly in line with
Howard’s (2000) results [60]. Our statistical analyses
also demonstrated that these significant associations
were not accounted for by the duration of illness. Thus,
the ability to recognise psychopathological symptoms of
schizophrenia to start psychopharmacological and psy-
chosocial interventions as soon as possible is becoming
a central issue in clinical practice [61]. Accordingly,
further investigation is needed to gain a better under-
standing of the age effect on the illness process of schi-
zophrenia spectrum disorders.
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